Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567460 | 0.85 | TUBB4A (0.49) | CREBBPNPC1KMT2AMAPTPOLB | |
| SCHEMBL6868530 | 0.83 | HPGD (0.55) | NPC1KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL11450490 | 0.82 | NPC1 (0.44) | CREBBPNPC1TSHRMAPTPOLB | |
| SCHEMBL15297323 | 0.82 | HSD17B2 (0.43) | KMT2AMEN1L3MBTL1MAPK1NUDT1 | |
| SCHEMBL11540405 | 0.81 | MTOR (0.39) | CREBBPNPC1KMT2ATSHRMEN1 | |
| SCHEMBL16759765 | 0.81 | ULK1 (0.47) | CREBBPNPC1KMT2AMEN1MAPK1 | |
| SCHEMBL15297504 | 0.81 | HSD17B2 (0.54) | NPC1KMT2AMEN1L3MBTL1MAPK1 | |
| SCHEMBL6870413 | 0.80 | CREBBP (0.39) | CREBBPNPC1KMT2AMEN1MAPT | |
| SCHEMBL3578888 | 0.78 | LMNA (0.53) | CREBBPNPC1KMT2AMEN1L3MBTL1 | |
| SCHEMBL6418376 | 0.78 | NR4A2 (0.51) | CREBBPNPC1L3MBTL1ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | claimed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | claimed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | claimed |
| EP-3074400-B1 | OCTAHYDRO-CYCLOBUTA [1,2-C;3,4-C']DIPYRROLE DERIVATIVES AS AUTOTAXIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
| EP-1280796-B1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6703397-B2 | REACTING A NITRILE GROUP CONTAINING INDOLE DERIVEATIVE WITH GUANIDINE OR SALT; USEFUL AS PROHYLAXIS OR THERAPEUTICAL TREATMENT OF INFECTIOUS DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030119857-A1 | Pyrimidinyl methyl indole derivatives with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-06-26 | — | — | US | disclosed |
| EP-1280796-A1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083474-A1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | CREBBP 3644/4885NPC1 2416/4885KMT2A 3271/4885 |
| US-20030119857-A1 | Pyrimidinyl methyl indole derivatives with antibacterial activity | IDO1, IDO2, AANAT | CREBBP 2199/4885NPC1 2939/4885KMT2A 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.